Respiratory viruses are responsible for substantial morbidity and mortality worldwide. Available prevention strategies are virus specific and have numerous shortcomings. Therefore, there is a need for development of new preventative antiviral strategies that offer a broad spectrum of protection.
ARMS-I is a first-in-class formulation that interrupts infection with a dual-action mechanism through 1) direct virucidal activity and 2) preventing contact between the virus and the host mucosal tissues through formation of a barrier.
Virucidal activity and the barrier to infection were evaluated separately against medically important enveloped respiratory viruses including influenza A/B, RSV, and Parainfluenza. The effective concentration of ARMS-I was determined for each virus by TCID50 for 1) direct virucidal activity and 2) reduction in virus infectivity using cell overlay. The effect of ARMS-I on the morphology and ultrastructure of the viral envelope was determined using transmission electron microscopy. ARMS-1 treated, Oseltamvir treated and untreated C57/BL6 mice were infected intranasally with a lethal dose (LD50, 8.0 x 103 pfu/mouse) of a mouse-adapted influenza strain (PR8). Mice body weights and survival were monitored daily for 14 days.
Effective concentration was determined to be 2% ARMS-I (20ug/ml cetylpyridinium chloride) reducing viral titer by ≥2logs TCID50/ml. Cells overlaid with as little as 27% of ARMS-I barrier components (94.5 mg/mL Glycerine; 1.08 mg/mL xanthan gum) also exhibited ≥2log TCID50/ml decrease. TEM examination showed that ARMS-I disrupted the integrity of the viral envelope and its morphology. Survival data showed that 4 out of 10 untreated mice infected with influenza strain succumbed to the disease while no deaths in the ARMS-I – treated group of mice occurred. There were no significant difference in survival between Arms1 or oseltamivir groups. ARMS-I treated mice exhibited higher average body weight compared to oseltamivir treated and untreated mice.
ARMS-I is effective in both disruption of viral envelopes as well as prevention of viral invasion against numerous respiratory tract viruses. ARMS-I reduces influenza-associated mortality and morbidity in vivo.
D. Popkin, None
H. Fujioka, None
P. Mukherjee, ARMS pharmacutical: Consultant , Consulting fee and Research grant
M. Ghannoum, ARMS Pharmaceutical: Has a financial interest in ARMS Pharmaceutical , Consulting fee